GlassScriptPhysician profile
Jeffrey C Poole
NPI 1518042134
$5,464.48
in general payments reported to CMS, 2019-2025
29 companies · $78.44 in 2025
The $78.44 reported for 2025 was less than what a typical Pediatric Dermatology provider received nationally (typical 2025 total: $302).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,122 · 2020: $393 · 2021: $1,070 · 2022: $1,015 · 2023: $968 · 2024: $819 · 2025: $78.44.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,865.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,865.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,262.16 | 2019-2024 | |
| Abbvie INC. | $1,059.64 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $478.10 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $472.15 | 2019-2024 | Dupixent |
| Ucb, INC. | $326.11 | 2019-2024 | Bimzelx, Cimzia |
| Lilly USA, LLC | $248.72 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Pfizer INC. | $242.31 | 2019-2024 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $202.19 | 2019-2022 | |
| Leo Pharma INC. | $166.05 | 2021-2024 | Adbry |
| Amgen INC. | $147.07 | 2019-2024 | Otezla |
| Janssen Biotech, INC. | $122.12 | 2019-2023 | Tremfya |
| Allergan, INC. | $102.18 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $95.53 | 2023-2024 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $85.77 | 2019-2024 | |
| Galderma Laboratories, L.P. | $78.67 | 2019-2024 | Aklief |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Krystal Biotech INC | $64.18 | 2023 | Vyjuvek |
| Incyte Corporation | $61.27 | 2021-2023 | Opzelura |
| Dermavant Sciences, INC. | $42.35 | 2023 | Vtama |
| Arcutis Biotherapeutics, INC. | $41.73 | 2023-2024 | Zoryve |
| Vyne Pharmaceuticals INC. | $28.62 | 2020 | |
| Nabriva Therapeutics, Plc | $22.24 | 2022 | |
| Almirall LLC | $21.68 | 2019 | |
| Dermira, INC. | $19.54 | 2021 | |
| Organogenesis INC. | $17.52 | 2024 | |
| Verrica Pharmaceuticals INC. | $16.20 | 2023 | Ycanth |
| Mylan Pharmaceuticals INC. | $16.13 | 2019 | |
| Biofrontera INC. | $12.84 | 2022 | |
| Mayne Pharma Commercial LLC | $11.41 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Poole listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.